Trial Profile
A Phase 1/2 Safety And Pharmacokinetic Study Of SU011248 In Combination With Docetaxel (Taxotere) And Prednisone In Patients With Metastatic Hormone Refractory Prostate Cancer (HRPC).
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary) ; Docetaxel; Prednisone
- Indications Prostate cancer
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 11 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 May 2010 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
- 30 Mar 2010 Actual patient number (93) added as reported by ClinicalTrials.gov.